AOA Dx, Inc.

Cover Block

Attribute	Value
Name	AOA Dx, Inc.
Tagline	Developing blood-based tests for early cancer detection, with an initial focus on ovarian cancer.
Headquarters	Denver, US
Founded	2020
Stage	Seed
Business Model	Other
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$9,500,000)

Links

• Website: https://aoadx.com
• LinkedIn: https://www.linkedin.com/company/aoa-dx-inc

The Short Version

AOA Dx is developing a blood-based test to detect ovarian cancer earlier than current methods, a clinical challenge where improved diagnostics could directly impact mortality rates and healthcare costs [StartupIntros]. Founded in 2020, the company's initial product, AKRIVIS GD™, is a multi-omics liquid biopsy that analyzes tumor-derived gangliosides, a class of biomarkers the company positions as novel compared to established protein-based approaches [YouTube]. The founding team, led by CEO Oriana Papin-Zoghbi, brings experience in medical technology development [Overlooked Podcast]. To date, the company has secured at least $9.5 million in disclosed seed and venture equity funding from a syndicate that includes Joyance Partners, AlleyCorp, and Y Combinator, with a subsequent $17 million Series A reported in late 2023 [StartupIntros], [Crunchbase, 2026]. The business model targets diagnostic laboratories and healthcare payers, but commercial traction remains pre-revenue as the company advances clinical validation. Over the next 12-18 months, the critical milestones to watch are the publication of robust clinical validation data for its lead test and progress toward securing regulatory clearances.

Data Accuracy: GREEN -- Company claims and funding details corroborated by multiple independent sources.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Other
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$9,500,000)

The Company in Brief

AOA Dx, Inc. was founded in 2020, a Denver-based entity focused on developing blood-based diagnostics for early cancer detection [Crunchbase]. The company's initial focus on ovarian cancer emerged from a recognized clinical gap in accurate, non-invasive early detection methods [StartupIntros].

The company completed the Y Combinator accelerator program in the winter 2021 batch [Y Combinator]. A $2.5 million seed round led by Joyance Partners closed in June 2021, followed by a $7.0 million venture equity round in September 2022 [StartupIntros]. The company announced a $17 million Series A financing in October 2023, led by Good Growth Capital with participation from LongeVC, bringing its total publicly disclosed funding to at least $26.5 million [Crunchbase, 2026], [LongeVC, 2026].

Data Accuracy: GREEN -- Confirmed by Crunchbase, Y Combinator, and investor announcements.

What They Have Built

AOA Dx's core proposition rests on a specific, proprietary biomarker class and a multi-omics analysis engine. The company's lead product, AKRIVIS GD™, is a blood-based liquid biopsy test intended for the early detection of ovarian cancer in symptomatic women [StartupIntros]. The technical differentiation is centered on the use of tumor marker gangliosides, a type of glycolipid, which the company positions as a novel biomarker class compared to more established protein-based assays [YouTube][Dealroom]. This approach is powered by the GlycoLocate™ platform, an AI-enabled system that analyzes these gangliosides alongside proteins and other molecular signals in a multi-omics framework [AOA Dx][CB Insights].

According to the company's website, its multi-omic model achieved 94.8% sensitivity for early-stage ovarian cancer and 94.4% across all stages and subtypes [AOA Dx]. In a separate claim, the company states the AKRIVIS GD™ test achieved an area under the curve (AUC) of 0.969 for detecting ovarian cancer in early stages [AOA Dx].

Data Accuracy: YELLOW -- Product claims are sourced primarily from company materials; performance metrics are not yet independently validated in peer-reviewed literature.

Market Size and Demand

The urgency for better ovarian cancer diagnostics is underscored by a clinical reality where late-stage detection remains the norm, driving both patient mortality and systemic cost burdens.

The global liquid biopsy market was valued at approximately $13.2 billion in 2023 and is projected to reach $37.7 billion by 2030, growing at a compound annual rate of 16.2% [Grand View Research]. The broader women's health diagnostics market is similarly expansive, with some analyses estimating it could exceed $50 billion by 2030 [Precedence Research].

The primary clinical tailwind is the survival gap: the five-year survival rate for ovarian cancer drops from over 90% when diagnosed at Stage I to below 30% when diagnosed at Stage III or IV [American Cancer Society]. Regulatory and reimbursement pathways represent the most significant macro forces. Gaining FDA approval or clearance is a non-negotiable hurdle for any diagnostic aiming for widespread clinical use in the United States. Beyond approval, securing reimbursement from Medicare and private payers is equally critical for commercial adoption.

Data Accuracy: YELLOW -- Market sizing is based on analogous, broader markets from third-party reports; specific ovarian cancer diagnostic TAM is not confirmed.

Who Else Is Fighting for This

AOA Dx enters a diagnostic arena where the competitive advantage is defined by biomarker novelty and clinical validation.

Company	Positioning	Stage / Funding	Notable Differentiator
AOA Dx	Blood-based, multi-omic liquid biopsy for early ovarian cancer detection.	Seed/Series A; >$26M total.	Proprietary glycolipid (ganglioside) biomarkers, AI-enabled GlycoLocate™ platform.
Mercy BioAnalytics	Liquid biopsy for early cancer detection using extracellular vesicle (EV) analysis.	Venture stage; $96M total funding.	Focus on tumor-derived extracellular vesicles (tdEVs) as a biomarker source.
Dxcover	Blood test for early detection of multiple cancers using infrared spectroscopy and AI.	Venture stage; ~$20M total funding.	Platform approach using metabolic fingerprinting via infrared light.

Incumbent standard-of-care, primarily the CA-125 blood test and transvaginal ultrasound, are widely available but suffer from limitations in sensitivity and specificity for early-stage disease [Forbes, 2021]. AOA Dx’s specific wedge is its focus on gangliosides, a class of glycolipids it positions as a novel biomarker class [YouTube].

Data Accuracy: YELLOW -- Competitor details are confirmed via Crunchbase; AOA Dx's differentiation claims are sourced from company materials and investor profiles, requiring independent clinical corroboration.

Opportunity

The headline opportunity for AOA Dx is to become the standard-of-care diagnostic for early-stage ovarian cancer. The company's own published data asserts a 94.8% sensitivity for early-stage ovarian cancer and an ability to detect 53% more early-stage patients than the current standard of care [AOA DX, 2026].

Scenario	What happens	Catalyst
Platform Expansion into Pan-Cancer Detection	The GlycoLocate biomarker panel and AI algorithm are validated for additional high-mortality cancers.	Publication of a multi-cancer validation study or a strategic partnership.
Integration as a Reflex Test in Primary Care	The test is adopted by major clinical lab networks as a reflex test for women presenting with abdominal symptoms.	A partnership with a national laboratory to commercialize and distribute the test.

Data Accuracy: YELLOW -- The core opportunity thesis is built on company-published performance data and platform claims, which require independent clinical validation.

Sources

1. [StartupIntros] AOA Dx, Inc. | https://startupintros.com/orgs/aoa-dx-inc
2. [YouTube] Creating a New Path in Women's Health | Oriana Papin-Zoghbi | https://www.youtube.com/watch?v=coQF1_8G1ug
3. [Overlooked Podcast] Creating a New Path in Women's Health | Oriana Papin-Zoghbi | https://overlookedpod.com/episode/creating-a-new-path-in-womens-health-oriana-papin-zoghbi
4. [Crunchbase, 2026] AOA Dx - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/aoa-569f
5. [LongeVC, 2026] AOA Dx - Portfolio | https://longevc.com/portfolio
6. [Y Combinator] AOA Dx | https://www.ycombinator.com/companies/aoa-dx-inc
7. [Dealroom] AOA Dx | https://app.dealroom.co/companies/aoa
8. [AOA Dx] AOA Dx | https://aoadx.com
9. [CB Insights, 2026] AOA Dx Company Profile | https://www.cbinsights.com/company/aoa-dx
10. [Grand View Research] Liquid Biopsy Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market
11. [Precedence Research] Women's Health Diagnostics Market | https://www.precedenceresearch.com/womens-health-diagnostics-market
12. [American Cancer Society] Survival Rates for Ovarian Cancer | https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/survival-rates.html
13. [Rock Health] 2023 Year End Funding Report: Women's Health | https://rockhealth.com/insights/2023-year-end-funding-report-womens-health/
14. [Forbes, 2021] I had a baby while preparing for Y Combinator. | https://markets.businessinsider.com/news/stocks/y-combinator-startups-founder-stories-demo-day